| GHRH | Growth Hormone-Releasing Hormone |
| AML | Acute Myeloid Leukemia |
| GHRH-R | Growth Hormone-Releasing Hormone Receptor |
| APL | Acute Promyelocytic Leukemia |
| ATRA | All-Trans-Retinoic Acid |
| ATO | Arsenic Trioxide |
| IGF-I | Insulin-Like Growth Factor 1 |
| SV | Splice Variant |
| pGHRH-R | Pituitary Growth Hormone-Releasing Hormone |
| RAA | ATRA/ATO Resistance |
| ELN | European LeukemiaNet |
| NCCN | National Comprehensive Cancer Network |
| FLT3 | Fms-Like Tyrosine Kinase 3 |
| FLT3-L | Fms-Like Tyrosine Kinase 3-Ligand |
| FLT3-ITD | Fms-Like Tyrosine Kinase 3 In-Frame Internal Tandem Duplication |
| FLT3-TKD | Fms-Like Tyrosine Kinase 3 Tyrosine Kinase Domain |
| R/R | Relapsed or Refractory |
| OS | Overall Survival |
| TFA | Trifluoroacetic Acid |
| MIA-602 (Ac) | Acetate Salt Form of MIA-602 |
| HMA | Hypomethylating Agent |
| LoDAC | Low-Dose Cytarabine |
| PML | Promyelocytic Leukemia |
| HSCT | Hematopoietic Stem Cell Transplant |
| PKA | Protein Kinase A |
| GPCR | G Protein-Coupled Receptor |
| AKT | Protein Kinase B |
| PI3K | Phosphoinositide 3-Kinase |
| cAMP | Cyclic Adenosine Monophosphate |
| IDH 1/2 | Isocitrate Dehydrogenase 1/2 |
| CBF | Core Binding Factor |
| NPM1 | Nucleophosmin 1 |
| KMT2A | Lysine Methyltransferase 2A |